Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Inclusion Criteria: * Histologic diagnosis of classical Hodgkin's lymphoma. Primary refractory or relapsed disease proven by biopsy at enrolling institution. * Stage I-III Hodgkin lymphoma (part 3) * Relapse or refractory disease following 1 line of multi-agent chemotherapy (not including pembro-GVD). * Eligible for HDT/ASCT * Achieved complete response (Deauville 3 or better) per clinical review following 2 cycles of pembro-GVD * Be willing and able to provide written informed consent/assent for the trial. * Be ≥ 18 years of age on day of signing informed consent. * Have measurable disease based on Lugano 2014 criteria * Have a performance status of 0 or 1 on the ECOG Performance Scale * Demonstrate adequate organ function as defined in table below * Demonstrate adequate organ function as defined in table below. Hematological\* * Absolute neutrophil count (ANC) ≥1000 /mcL * Platelets ≥50,000 / mcL * Hemoglobin ≥8 g/dL Renal * Serum creatinine OR ≤1.5 X upper limit of normal (ULN) OR * Measured or calculated creatinine clearance (eGFR can also be used in place of creatinine) ≥60 mL/min for subject with creatinine levels \> 1.5 X institutional ULN Hepatic\* * Serum total bilirubin ≤ 1.5 X ULN OR ≤ 3 X ULN for subjects with liver metastases * AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases Pulmonary * Hemoglobin-adjusted diffusing capacity for carbon monoxide ≥50% (If unadjusted DLCO is \>/= 50% then there is no need to calculate adjusted)…